UK Biotech Companies: How to Navigate EU and US Market Entry Post-Brexit

Before Brexit:

• EMA approval covered all EU member states plus the UK
• UK was a major contributor to EMA scientific committees
• Single regulatory submission, single approval

After Brexit:

• MHRA operates independently with its own approval process
• EMA approval covers only EU/EEA member states — not the UK
• UK companies must submit separately to both MHRA and EMA
• No automatic mutual recognition between MHRA and EMA decisions

• The EU Clinical Trials Regulation (CTR) no longer applies in the UK
• UK follows its own clinical trials framework under the Medicines and Healthcare products Regulatory Agency
• Multi-country trials spanning UK and EU require separate applications and compliance with both frameworks
• Clinical trial data generated in the UK is still accepted by EMA and FDA, but trial design must meet each agency's requirements

• Batch testing and release: Products manufactured in the UK may require re-testing for EU market release by an EU-based Qualified Person (QP)
• Import requirements: UK-manufactured products are now treated as third-country imports in the EU
• Supply chain planning must account for customs, regulatory compliance, and potential border delays

• UK is no longer covered by EU-wide patent regulations
• Supplementary Protection Certificates (SPCs) must be filed separately in the UK and EU
• Freedom to operate analyses must now cover both jurisdictions independently

Innovative Licensing and Access Pathway (ILAP) ILAP is designed to accelerate patient access to innovative therapies. It offers:

• A single point of entry for regulatory, HTA (NICE), and NHS engagement
• Innovation Passports for qualifying products
• Coordinated development and access planning

Reliance Procedure The MHRA can leverage assessments from other trusted regulators (EMA, FDA, TGA, Health Canada) to expedite UK approvals. This means:

• If you already have EMA or FDA approval, MHRA review can be significantly faster
• Reduced duplication of regulatory effort

Key considerations for UK companies:

• You need an EU-based Marketing Authorization Holder (MAH) — a UK entity can no longer serve as MAH for EU submissions
• An EU-based Qualified Person for Pharmacovigilance (QPPV) is required
• Regulatory correspondence and inspections will be conducted through EU-based entities

EMA approval is only the beginning. Each EU member state conducts its own:

• Health Technology Assessment
• Pricing negotiations
• Reimbursement decisions

1. Establish an EU legal entity or partner with an EU-based organization for MAH and pharmacovigilance
2. Engage EU regulatory consultants familiar with centralized procedure requirements
3. Begin HTA preparation during Phase 2 — EU payer evidence requirements should inform trial design
4. Develop a launch sequencing strategy that optimizes pricing across reference-dependent markets

• Standard NDA/BLA: Full regulatory submission with complete clinical data package
• Fast Track: Expedited development and review for serious conditions with unmet need
• Breakthrough Therapy: Intensive FDA guidance and potential rolling review for therapies demonstrating substantial improvement
• Accelerated Approval: Approval based on surrogate endpoints, with post-marketing confirmatory requirements
• Priority Review: 6-month review target instead of standard 10 months

Important for UK companies:

• FDA accepts clinical data from non-US sites, but Phase 3 trials should include US clinical sites
• An FDA Pre-IND meeting is highly recommended to align on development strategy
• US regulatory requirements around Chemistry, Manufacturing, and Controls (CMC) are rigorous — plan manufacturing validation early

Market access:

• No centralized HTA — but PBMs, commercial insurers, and Medicare/Medicaid each have their own formulary processes
• Pricing is market-driven but increasingly scrutinized under the Inflation Reduction Act
• Specialty pharmacy and buy-and-bill distribution models require specific infrastructure

Commercial presence:

• Options range from building a US subsidiary to licensing US rights to an established partner
• A US subsidiary requires significant investment: regulatory affairs, medical affairs, market access, sales force, patient services
• Many UK biotechs opt for a US partnership for their first product launch, then build internal capabilities for subsequent products

1. Engage FDA early through Pre-IND meetings and designations (Fast Track, Breakthrough)
2. Include US clinical sites in pivotal trials
3. Begin US payer advisory boards during Phase 2 to understand formulary requirements
4. Decide on build vs. partner for US commercialization 18-24 months before anticipated approval
5. Budget appropriately — US market entry typically requires $30-50M+ for self-commercialization

1. Design one global clinical programme

• Select endpoints, comparators, and patient populations that satisfy all three agencies
• Use FDA guidance as the baseline (typically most demanding) and layer in MHRA/EMA requirements
• Run multi-country trials with sites across UK, EU, and US

2. Harmonize regulatory submissions where possible

• Use the Common Technical Document (CTD) format accepted by all three agencies
• Prepare a core dossier and customize modules for each agency's specific requirements
• Leverage MHRA reliance procedures to reduce duplication

3. Align timelines strategically

• Consider filing with FDA first if US is your priority market
• Use MHRA reliance on FDA approval to fast-track UK authorization
• Submit to EMA on a timeline that optimizes EU launch sequencing

4. Build a regulatory team with multi-jurisdictional expertise

• In-house or through experienced advisors, ensure your regulatory strategy team understands the nuances of all three systems
• Avoid the common mistake of hiring separate siloed teams for each jurisdiction — coordination is key

• UK funding sources: Innovate UK, UK Research and Innovation, British Patient Capital, UK-based life science VCs
• EU funding: Horizon Europe (UK is now an associated country), EIC Accelerator
• US funding: NIH grants (SBIR/STTR for qualifying companies), US-based VCs
• Partnering: Licensing deals that fund global development in exchange for regional commercial rights
• Public markets: AIM (London), Nasdaq, Euronext — each offers access to different investor bases